RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1

RBC Capital analyst Lisa Walter has maintained a 'Sector Perform' rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) while lowering the price target from $5 to $1. This adjustment reflects a significant reduction in expectations for the company's stock performance.